Out-licensing Opportunities
PankoMab™ & KaroMab™:
Therapeutic antibodies for immunotoxin platforms
NEMOD is developing the two tumor specific antibodies PankoMab™ and KaroMab™ in a radiolabeled format. PankoMab™ recognizes a novel tumor epitope on MUC1, KaroMab™ targets the Thomsen-Friedenreich antigen. NEMOD offers licenses for both antibodies (and further potentials, e.g. Mabs against the tumor specific Lewis-Y antigen and Globo H) for the development of all non-radioactive formats.
Both antibodies are of murine origin and are available in different formats (chimeric antibodies, multibodies). In addition, humanized antibody constructs are available for KaroMab.
Development Status: Advanced preclinical
PankoMetin™: Antibody for liver metastases prevention
PankoMetin™ is developed as an TF-specific chimeric or humanized IgM for the prevention of liver metastases. As shown in a mouse model the murine PankoMetin™ can inhibit TF-mediated liver metastasis. TF is an independent prognostic factor for liver metastases and clinical outcome. PankoMetin™ is aimed to be applied in the clinical setting to prevent or reduce liver metastases of TF-positive cancers after surgery.
Development status: preclinical studies finished; chimeric PankoMetin producing cell line and humanized constructs are available.
PankoVAC™: Allogenic cell vaccine
PankoVAC™ is being developed as an allogenic vaccine. Compared to autologous tumor cell vaccines PankoVAC™ shows all the advantages of an off-the-shelf refinement and production. Master cells of hematopoetic origin were glycoengineered to express a series of pan-carcinomic tumor antigens including carbohydrate tumor antigens. These antigens are more specific for tumor cells and more widespread on these cells than conventional tumor-associated antigens. In addition, the master cells express several co-immunostimulatory molecules.
Development status: Early preclinical
|
